Teleflex Launches New Website for Teleflex ISIS(R) HVT(TM), the First Comprehensive Endotracheal Tube

October 31, 2011

LIMERICK, Pa., Oct 31, 2011 (BUSINESS WIRE) -- Teleflex Incorporated (NYSE: TFX) At Teleflex, we are committed to providing clinically significant products that enable healthcare providers to improve outcomes and enhance patient and clinician safety. Keeping with this mission, we are pleased to announce a new customer website for the Teleflex ISIS HVT endotracheal tube.

The new site, isishvt.com, offers information about providing better access to best clinical practices using ISIS HVT. With an integrated suction port and separate suction line, ISIS HVT allows for subglottic secretion suctioning on demand. Clinicians can now be free from the burden of choosing which endotracheal tube is best for the patient at the time of intubation. When needed, the suction line attaches to the ISIS HVT via a secure locking connection. This versatile design allows for use of one endotracheal tube to meet the needs of patients requiring both short- and long-term ventilation.

During mechanical ventilation, secretions from the upper respiratory tract accumulate above the endotracheal tube cuff. Studies have shown that these secretions can seep past the cuff into the lower tract, increasing the incidence of Ventilator-Associated Pneumonia (VAP).[1] VAP is one of the most common infections acquired by adults and children in intensive care units today.[2] Suctioning of secretions that pool above the endotracheal tube cuff has been proven as an effective strategy in preventing early-onset VAP.[3]

The clinical challenge encountered today is that the endotracheal tube selected for initial intubation does not always allow for easy access to this valuable practice. The versatile design of the ISIS HVT eliminates the need to be selective during initial intubation, providing better access by increasing the number of patients that can be viable candidates for subglottic secretion suctioning, a clinically proven strategy for VAP reduction.[3]

Visit http://www.isishvt.com to learn more.

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,600 people worldwide and serves healthcare providers in more than 130 countries. For additional information about Teleflex please refer to http://www.teleflex.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, ISIS and HVT are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

[1] American Thoracic Society. Consensus Statement: Hospital Acquired Pneumonia in Adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. *Am J Respir Crit Care Med*. 1996;151:1711-1725.

[2] Coffin S MD, MPH, Klompas M MD, Classen D MD, et al. Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals. *Infect Control Hosp Epidemiol* 2008; 29:S31-S40.

[3] Dezfulian C, Shojania K, Collard HR, Kim HM, Matthay MA, Saint S. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. *Am J Med* 2005; 118:11-18.

SOURCE: Teleflex Incorporated

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President Investor Relations
610-948-2836